What this teaches
A seed VC analyzes 71 tech IPOs and finds no correlation between capital raised and outcome quality: the most efficient companies returned more per dollar than the most funded. Argues overcapitalization is a drug with real side effects.
Why it matters
Data-backed counterweight to the raise-as-much-as-you-can reflex, from an investor whose incentives run the other way.
Key lessons
- Capital raised does not predict success; efficiency often does
- Every dollar raised is a claim on your exit and a constraint on your options
- Treat VC like a powerful drug: dose carefully
Founder Collective
See their stage, check size, and thesis in the VCMatch investor index. View profile →